EZETIMIBE AND SIMVASTATIN MARKET

INTRODUCTION

Ezetimibe/simvastatin is a drug combination used for the treatment of dyslipidemia. It is a combination of ezetimibe (known as Zetia in the United States) and the statin drug simvastatin (known as Zocor in the US).Ezetimibe reduces blood cholesterol by acting at the brush border of the small intestine and inhibiting the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver.

Simvastatin is an HMG-CoA reductase inhibitor or statin. It works by blocking an enzyme that is necessary for the body to make cholesterol. Generic versions were approved. The combination preparation is marketed by Merck & Co. under the trade names Vytorin in the US and Inge in the European Union. In the previous years , it was the top most commonly prescribed medication in the United States, with more than eight hundred thousand prescriptions.

The combination of ezetimibe and simvastatin is currently the only product to treat both sources of cholesterol; absorption in the intestine of both biliary and dietary cholesterol, and production in the liver and peripheral tissues. It is thought that the treatment of high cholesterol from both sources is likely to result in lower cholesterol levels, particularly LDL cholesterol. In a clinical study, it was shown that the combination of ezetimibe and simvastatin was superior to atorvastatin in lowering LDL cholesterol.

EZETIMIBE AND SIMVASTATIN MARKET SIZE AND FORECAST

The Global Ezetimibe and Simvastatin Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

EZETIMIBE AND SIMVASTATIN MARKET NEW PRODUCT LAUNCH

CIPLA ezetimibe and simvastatinEzetimibereduces the amount of cholesterol absorbed by the body.Simvastatinis in a group of drugs called HMG CoA reductase inhibitors, or "statins.

"Ezetimibe and simvastatin is a combination medicine that is used to lower blood levels of "bad" cholesterol (low-density lipoprotein, or LDL), to increase levels of "good" cholesterol (high-density lipoprotein, or HDL), and to lower triglycerides (a type of fat in the blood).

Ezetimibe and simvastatin is used together with a low-fat diet and other treatments to lower total cholesterol in adults and children who are at least 10 years old. It is not known whether ezetimibe and simvastatin reduces your risk ofheart disease.

EZETIMIBE AND SIMVASTATIN MARKET COMPANY PROFILE

• CIPLA 
• GLENMARK
• DR REDDY
• SUN PHARMA
• ALKEM

THIS EZETIMIBE AND SIMVASTATIN MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many Ezetimibe and Simvastatin are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Ezetimibe and Simvastatin and key vendor selection criteria
3. Where is the Ezetimibe and Simvastatin manufactured? What is the average margin per unit?
4. Market share of Global Ezetimibe and Simvastatin market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Ezetimibe and Simvastatin in-house
6. key predictions for next 5 years in Global Ezetimibe and Simvastatin market
7. Average B-2-B Ezetimibe and Simvastatin market price in all segments
8. Latest trends in Ezetimibe and Simvastatin market, by every market segment
9. The market size (both volume and value) of the Ezetimibe and Simvastatin market in 2024-2030 and every year in between?
10. Production breakup of Ezetimibe and Simvastatin market, by suppliers and their OEM relationship